Quarterly ResultSep 11, 2026, 09:06 AM
Ping An Biomedical Reports Profitability Turnaround, Revenue Declines
AI Summary
Ping An Biomedical Co., Ltd. has released its unaudited condensed consolidated financial statements for the six months ended March 31, 2026. The company reported a significant turnaround in profitability, with net income reaching RMB 4.83 million compared to a net loss of RMB 4.23 million in the same period last year. Revenue, however, decreased to RMB 9.59 million from RMB 18.23 million. The company also saw a substantial increase in total assets and a significant boost in shareholders' equity, largely attributed to a private placement. Cash flows from financing activities were strong, reflecting the proceeds from this placement.
Key Highlights
- Ping An Biomedical reported revenue of RMB 9.59 million for the six months ended March 31, 2026, a decrease from RMB 18.23 million in the prior year period.
- Net income turned positive to RMB 4.83 million for the six months ended March 31, 2026, compared to a net loss of RMB 4.23 million in the prior year period.
- Earnings per share (EPS) was RMB 0.10 for the six months ended March 31, 2026, up from a loss of RMB 0.24 per share in the prior year period.
- Total assets increased to RMB 100.22 million as of March 31, 2026, from RMB 68.41 million as of September 30, 2025.
- Total liabilities decreased to RMB 22.04 million as of March 31, 2026, from RMB 23.17 million as of September 30, 2025.
- Shareholders' equity significantly increased to RMB 78.18 million as of March 31, 2026, from RMB 45.24 million as of September 30, 2025, driven by a private placement.
- The company saw a substantial increase in cash flows from financing activities, reaching RMB 28.41 million for the six months ended March 31, 2026, primarily due to proceeds from a private placement.
Price Impact
More from PASW